Pfizer Launches Cejemly® (Sugemalimab) for Phase III NSCLC Indication in China

July 17: Pfizer's innovative oncology immunotherapy drug, Zhejie Stone® (generic name: Sugemalimab Injection), held a launch event for its second indication targeting Stage III non-small cell lung cancer (NSCLC). Pfizer China stated that Zhejie Stone® is the only tumor immunotherapy drug in China approved for both Stage III and Stage IV NSCLC indications.